60p on the way What is ther not to like14 Jan 2025 18:16
The Board is confident in the outlook for the remainder of the year and confirms that both revenue and profit will significantly exceed market expectations* for the full year.
Successful launches in over ten countries including key European markets such as France, Italy and Spain, with further launches expected in the second half of 2024 in both Europe and Rest of World.
Extension of licencing agreement with Cooper to 2029.
"We look forward with excitement to the second half of 2024 with further launches already underway for Eroxon® and in particular the launch in the US, the largest consumer healthcare market in the world, by our distribution partner Haleon."